Susan M. Domchek, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Headshot of Susan M. Domchek, MD
Penn Medicine Provider

About me

  • Executive Director, Basser Center for BRCA
  • Director, MacDonald Women’s Cancer Risk Evaluation Center
  • Basser Professor in Oncology

My education and training

  • Medical School: Harvard University
  • Residency: Massachusetts General Hospital
  • Fellowship: Dana-Farber Cancer Institute

Spoken languages

English
English

Reviews

Average Rating

515 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
June 2026
dr domchek is the best there is
Anonymous
May 2026
i would want others to receive the same level of care and help.
Anonymous
May 2026
dr domchek is amazing
Anonymous
May 2026
i was under the impression we would be discussing results of genetic testing in more detail than phone call. got pretty much the same info, but left with impression that i paid for a visit to have a doctor preach about quitting smoking and persuade me to recruit a family member for genetic testing for research.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Domchek is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Aggarwal R, Italiano A, Domchek SM, Goodman O, Postel-Vinay S, Garcia-Donas J, Dorff T, Reichert ZR, Vinceneux A, Shore N, Marshall CH, Armenia J, Parr G, Kmieciak A, Lukashchuk N, Murina O, Slade D, Shah N, Loembé B, Dean E, Sanai E, Abida W. Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study. , Cancer Res Commun., 6(7): 2026


Buckley KH, Zhu Y, Dinh K, Hausler R, Gala R, Spiegel SR, Delgado R, Clay DG, Kelly GM, Brower J, Domchek SM, Maxwell KN, Katona BW. Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers. , Int J Cancer: 2026


Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe CS, Mann D, Spielman K, Wong G, Haas NB, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova AO, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN. Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer. , J Natl Compr Canc Netw.: 2026,1-7


Nguyen AA, Cohen EA, Ehsan S, Mankowski WC, Barufaldi B, Gillette R, Domchek SM, Kontos D, McCarthy AM. Longitudinal Association of Quantitative Background Parenchymal Enhancement with Breast Cancer Risk Among Women with BRCA1/2 Pathogenic Variants. , Cancer Epidemiol Biomarkers Prev.: 2026


Ongaro G, Salafia C, Sheikh R, Schofield E, Clark DF, Ebrahimzadeh J, Chittenden A, Stopfer JE, Brower J, Symecko H, Ovadia H, Husband A, Barr H, Mukherjee S, Hay JL, Stadler ZK, Offit K, Garber JE, Domchek SM, Robson ME, Hamilton JG. The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in Women with Pathogenic BRCA1/2 Variants. , Genet Med.: 2026


Schopf C, Domchek SM, Tice JA, Eby PR, Mann R, Lehman CD, Cozzi A, Trivedi H, Lee JM. Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review. Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review. , AJR Am J Roentgenol.: 2026


Abdou Y, Rozenblit M, Trapani D, Zerdes I, Boudreau E, Zhou Y, Adam V, Barrios C, Bousrih C, Branch V, Carey LA, Cameron D, Chen S, Chua BH, Davidson NE, Domchek SM, El-Abed S, El-Ashry D, Flowers M, Foldi J, Garber J, Goulioti T, Hodgdon C, Hung JL, Klar N, Norton L, Parajuli R, Piccart M, Pollastro T, Santa-Maria CA, Schumacher-Wulf E, Stecklein SR, Thulin A, Tovey H, Winer E, Wolff AC, Lin NU, O'Reilly S. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). NPJ 2026 May 11;12(1):69. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2) , NPJ Breast Cancer, 11:12(1): 2026,69


Abdou Y, Rozenblit M, Trapani D, Zerdes I, Boudreau E, Zhou Y, Adam V, Barrios C, Bousrih C, Branch V, Carey LA, Cameron D, Chen S, Chua BH, Davidson NE, Domchek SM, El-Abed S, El-Ashry D, Flowers M, Foldi J, Garber J, Goulioti T, Hodgdon C, Hung JL, Klar N, Norton L, Parajuli R, Piccart M, Pollastro T, Santa-Maria CA, Schumacher-Wulf E, Stecklein SR, Thulin A, Tovey H, Winer E, Wolff AC, Lin NU, O'Reilly S. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). , NPJ Breast Cancer, 12(1): 2026,69


Callaway MK, Comfort L, Anandan D, Sharma R, Florez N, Lyons TR, Germain D, Cho KR, Rochelson BL, Bonanno C, Oktay K, Roychoudhury S, O'donnell E, Barakat R, Marquardt J, Bianchi DW, Cardonick E, Norton L, Partridge AH, Domchek SM, Borges VF, Amant F, Dos Santos CO. Cancer During Pregnancy: Navigating Clinical and Research Challenges. , Curr Oncol., 33(5): 2026,296


Schopf C, Domchek SM, Tice JA, Eby PR, Mann R, Lehman CD, Cozzi A, Trivedi H, Lee JM. . 2026 May 6. Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review. , AJR Am J Roentgenol.: 2026